The successful translation of the dasatinib and quercetin (D+Q) senolytic combination from preclinical models to human clinical trials has marked a major milestone in the field of geroscience. As the first senolytic therapy to be tested in humans, D+Q has paved the way for a new era of medicine focused on targeting the fundamental mechanisms of aging. This article explores the future of D+Q in clinical medicine, from its potential to treat a growing list of age-related diseases to the development of next-generation senolytics.
Expanding the Scope of Clinical Trials
Following the initial success of the D+Q pilot study in idiopathic pulmonary fibrosis (IPF), a number of clinical trials have been launched to evaluate the safety and efficacy of this senolytic combination in a variety of other age-related conditions. These include chronic kidney disease, osteoarthritis, Alzheimer's disease, and frailty. The results of these trials will provide valuable insights into the therapeutic potential of D+Q across a broad spectrum of diseases.
Intermittent Dosing and Long-Term Safety
One of the key advantages of senolytic therapy is that it can be administered intermittently. Because it takes time for senescent cells to re-accumulate, it is not necessary to take senolytics on a continuous basis. This intermittent dosing schedule is not only more convenient for patients but also reduces the risk of side effects. Long-term studies are needed to confirm the safety and efficacy of intermittent D+Q therapy over extended periods.
The Quest for Next-Generation Senolytics
While D+Q has been a groundbreaking senolytic therapy, it is not without its limitations. Dasatinib is a chemotherapy drug with a number of potential side effects. As a result, there is a great deal of interest in developing next-generation senolytics that are more potent, more specific, and have a better safety profile. The knowledge gained from studying D+Q will be invaluable in the development of these new and improved senolytic drugs.
| Clinical Trial | Condition | Status |
|---|---|---|
| STAX-L | Idiopathic Pulmonary Fibrosis | Completed |
| STAX-CKD | Chronic Kidney Disease | Recruiting |
| ALSEN | Alzheimer's Disease | Recruiting |
| UNITY | Osteoarthritis | Recruiting |
Key Takeaways
- The dasatinib and quercetin (D+Q) senolytic combination has shown great promise in clinical trials.
- D+Q is being evaluated for the treatment of a wide range of age-related diseases.
- Intermittent dosing may be a safe and effective way to administer senolytic therapy.
- The development of next-generation senolytics is a major focus of research in the field of geroscience.
References
- Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., ... & Kirkland, J. L. (2019). Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine, 40, 554-563.
- Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., ... & Kirkland, J. L. (2019). Senolytics decrease senescent cells in humans: a first-in-human, open-label, pilot study. EBioMedicine, 47, 446-456.
- Kirkland, J. L., & Tchkonia, T. (2020). Senolytic drugs: from discovery to translation. Journal of internal medicine, 288(5), 518-536.
- Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022). Cellular senescence and senolytics: the path to the clinic. Nature medicine, 28(8), 1556-1568.
Medical Disclaimer: The information provided in this article is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment.
